Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab and Evorpacept in Advanced HER2-expressing Cancer
NCT05027139Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Sep 2021
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab, evorpacept in Human epidermal growth factor receptor 2 positive cancer, sponsored by Jazz Pharmaceuticals plc. Started Sep 2021; status: completed.
02
Drugs
zanidatamabevorpacept
03
Conditions
Human epidermal growth factor receptor 2 positive cancer
Beyond the preview
Go deeper on NCT05027139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027139.